Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients

被引：28

作者：

Rocio, Carolina ^{[1
]}

Amato, Valdir Sabbaga ^{[1
]}

Camargo, Raphael A. ^{[1
]}

Tuon, Felipe F. ^{[2
]}

Nicodemo, Antonio Carlos ^{[1
]}

机构：

[1] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil

[2] Univ Fed Parana, Clin Univ Hosp, Div Infect Dis, BR-80060000 Curitiba, PR, Brazil

来源：

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2014年 / 108卷 / 03期

关键词：

Amphotericin B; Leishmania treatment; Leishmaniasis;

D O I：

10.1093/trstmh/tru011

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background: Studies assessing the efficacy of liposomal amphotericin B (LAB) in the treatment of patients with mucosal leishmaniasis (ML) are very scarce in the literature and an optimal dose regimen has not yet been defined. Methods: We performed a retrospective and descriptive analysis from records of 16 patients with ML treated with LAB. The mean daily dose of LAB was 2.5 mg/kg/day. Results: Healing of the lesion was observed in 14 (88%) of the 16 patients. The mean cumulative doses, excluding the two treatment failures, were 2265 mg and 33 mg/kg. Conclusion: Liposomal amphotericin B in the cumulative dose of 30 to 35 mg/kg was able to achieve 100% effectiveness.

引用

页码：176 / 178

页数：3

共 50 条

[21] Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients
López-Vélez, R
Videla, S
Márquez, M
Boix, V
Jiménez-Mejías, ME
Górgolas, M
Arribas, JR
Salas, A
Laguna, F
Sust, M
Cañavate, C
Alvar, J
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (03) : 540 - 543
[22] Liposomal amphotericin B and HIV-associated visceral leishmaniasis - Concerns about nephrotoxicity and administration schedule
Sabbatani, S
Manfredi, R
Marinacci, G
Pavoni, M
Nafissi, M
Chiodo, F
CLINICAL DRUG INVESTIGATION, 2005, 25 (01) : 85 - 87
[23] New formulations and derivatives of amphotericin B for treatment of leishmaniasis
Golenser, J
Domb, A
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2006, 6 (02) : 153 - 162
[24] First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France
Minodier, P
Robert, S
Noël, G
Blanc, P
Retornaz, K
Garnier, JM
ARCHIVES DE PEDIATRIE, 2005, 12 (07): : 1102 - 1108
[25] A new prospect on canine leishmaniasis: Treatment with amphotericin B
Lamothe, J
PRATIQUE MEDICALE ET CHIRURGICALE DE L ANIMAL DE COMPAGNIE, 1997, 32 (02): : 133 - 141
[26] Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations
Frezard, Frederic
Aguiar, Marta M. G.
Ferreira, Lucas A. M.
Ramos, Guilherme S.
Santos, Thais T.
Borges, Gabriel S. M.
Vallejos, Virginia M. R.
De Morais, Helane L. O.
PHARMACEUTICS, 2023, 15 (01)
[27] APPARENTLY SUCCESSFUL TREATMENT OF 2 CASES OF POST KALA-AZAR DERMAL LEISHMANIASIS WITH LIPOSOMAL AMPHOTERICIN-B
HASHIM, FA
KHALIL, EAG
ISMAIL, A
ELHASSAN, AM
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1995, 89 (04) : 440 - 440
[28] Development of liposomal amphotericin B dry powder inhaler formulation
Shah, SP
Misra, A
DRUG DELIVERY, 2004, 11 (04) : 247 - 253
[29] Development of dextrin-amphotericin B formulations for the treatment of Leishmaniasis
Silva-Carvalho, R.
Fidalgo, J.
Melo, K. R.
Queiroz, M. F.
Leal, S.
Rocha, H. A.
Cruz, T.
Parpot, P.
Tomas, A. M.
Gama, M.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2020, 153 : 276 - 288
[30] Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis in HIV/AIDS Patients in India-A Pilot Pharmacokinetic Study
Jadhav, Manoj
Jadhav, Priyanka
Shinde, Vishal
Kadam, Prashant
Kshirsagar, Nilima
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (01): : 48 - 52

← 1 2 3 4 5 →